Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 4/20 | 0.35 |
| ▸ | MAP2K3 | P46734 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 2/20 | 0.31 |
| ▸ | CDK8 | P49336 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378664 | 0.95 | SRC (0.38) | SRCKDRBRAFCDC7MAP2K3 | |
| SCHEMBL7957179 | 0.59 | KMT2A (0.40) | SRCKDRBRAFCDC7MAP2K3 | |
| SCHEMBL14917438 | 0.57 | SRC (0.48) | SRCKDRBRAFCDC7MAP2K3 | |
| SCHEMBL6314872 | 0.56 | KMT2A (0.50) | SRCKDRBRAFCDC7MAP2K3 | |
| SCHEMBL7005018 | 0.56 | KDM4C (0.36) | BRAF | |
| SCHEMBL7946362 | 0.56 | CDC7 (0.50) | CDC7CDK9CDK2CCNCCDK8 | |
| SCHEMBL28052676 | 0.55 | SCN9A (0.57) | CDC7MAP2K3CSNK1DDBF4CCNE1 | |
| SCHEMBL29911672 | 0.55 | SCN9A (0.57) | CDC7MAP2K3CSNK1DDBF4CCNE1 | |
| SCHEMBL20379181 | 0.55 | MAPK1 (0.61) | — | |
| SCHEMBL14833703 | 0.54 | SRC (1.00) | SRCKDRBRAFCDC7MAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | claimed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | claimed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | claimed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | claimed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | claimed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | GSK3B, GSK3A, GSKIP | SRC 350/4885KDR 3446/4885BRAF 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.